Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).
Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).
Low‐molecular‐weight heparin (LMWH) showed no clear difference in pulmonary embolism (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).
Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).